The University of Texas.
J Appl Clin Med Phys. 2014 May 8;15(3):4742. doi: 10.1120/jacmp.v15i3.4742.
As part of the approval process for the use of scattered or uniform scanning proton therapy in National Cancer Institute (NCI)-sponsored clinical trials, the Radiological Physics Center (RPC) mandates irradiation of two RPC anthropomorphic proton phantoms (prostate and spine). The RPC evaluates these irradiations to ensure that they agree with the institutions' treatment plans within criteria of the NCI-funded cooperative study groups. The purpose of this study was to evaluate the use of an anthropomorphic spine phantom for proton matched-field irradiation, and to assess its use as a credentialing tool for proton therapy beams. We used an anthropomorphic spine phantom made of human vertebral bodies embedded in a tissue substitute material called Muscle Substitute/Solid Rigid Number 4 (MS/SR4) comprising three sections: a posterior section containing the posterior surface and the spinous processes, and left and right (L/R) sections containing the vertebral bodies and the transverse processes. After feasibility studies at three institutions, the phantom, containing two thermoluminescent dosimeters (TLDs) for absolute dose measurements and two sheets of radiochromic film for relative dosimetry, was shipped consecutively to eight proton therapy centers participating in the approval study. At each center, the phantom was placed in a supine or prone position (according to the institution's spine treatment protocol) and imaged with computed tomography (CT). The images then were used with the institution's treatment planning system (TPS) to generate two matched fields, and the phantom was irradiated accordingly. The irradiated phantom was shipped to the RPC for analysis, and the measured values were compared with the institution's TPS dose and profiles using criteria of ± 7% for dose agreement and 5 mm for profile distance to agreement. All proton centers passed the dose criterion with a mean agreement of 3% (maximum observed agreement, 7%). One center failed the profile distance-to-agreement criterion on its initial irradiation, but its second irradiation passed the criterion. Another center failed the profile distance-to-agreement criterion, but no repeat irradiation was performed. Thus, seven of the eight institutions passed the film profile distance-to-agreement criterion with a mean agreement of 1.2 mm (maximum observed agreement 5 mm). We conclude that an anthropomorphic spine phantom using TLD and radiochromic film adequately verified dose delivery and field placement for matched-field treatments.
作为美国国家癌症研究所(NCI)赞助的临床试验中使用分散或均匀扫描质子治疗批准程序的一部分,放射物理学中心(RPC)要求辐照两个 RPC 人体质子体模(前列腺和脊柱)。RPC 评估这些辐照以确保它们符合机构的治疗计划,符合 NCI 资助的合作研究小组的标准。本研究的目的是评估使用人体脊柱体模进行质子匹配场照射,并评估其作为质子治疗束认证工具的用途。我们使用了一种由嵌入在称为肌肉替代物/固体刚性 4 号(MS/SR4)的组织替代材料中的人体椎骨制成的人体脊柱体模,该体模由三个部分组成:包含后表面和棘突的后部分,以及包含椎骨和横突的左/右(L/R)部分。在三个机构进行了可行性研究之后,该体模包含两个用于绝对剂量测量的热释光剂量计(TLD)和两张用于相对剂量测量的光致变色胶片,随后连续运往参加批准研究的八个质子治疗中心。在每个中心,根据机构的脊柱治疗方案,将体模置于仰卧位或俯卧位,并进行计算机断层扫描(CT)成像。然后,使用机构的治疗计划系统(TPS)生成两个匹配场,并相应地辐照体模。辐照后的体模被运送到 RPC 进行分析,并使用剂量协议的±7%和轮廓距离协议的 5mm 的标准,将测量值与机构的 TPS 剂量和轮廓进行比较。所有质子中心都通过了剂量标准,平均符合率为 3%(最大观察符合率为 7%)。一个中心在其初始辐照时未能通过轮廓距离符合标准,但第二次辐照通过了标准。另一个中心未能通过轮廓距离符合标准,但没有进行重复辐照。因此,八个机构中的七个机构通过了胶片轮廓距离符合标准,平均符合率为 1.2mm(最大观察符合率为 5mm)。我们得出结论,使用 TLD 和光致变色胶片的人体脊柱体模充分验证了匹配场治疗的剂量传递和场放置。